Oncology
Aptamer therapeutics in Oncology can be configured in various ways:
Antagonist of protein-protein or receptor-ligand interactions
Aptamer–drug conjugates (ApDCs)
Aptamer-siRNA conjugates
Aptamer bi-specifics
Her3 Inhibitor Aptamer’s Intrinsic Anti-tumor Activity Can Be Augmented And Potency Improved By Conjugation to DM1
Aptamer (GRX1461) inhibits BXPC3 tumor growth in a dose dependent manner
Highest dose is equivalent to gemcitabine
Aptamer toxin conjugate (GRX1462) has improved potency
Highest dose completely inhibits tumor growth
Contact
© 2022 Guardian Therapeutics. All rights reserved.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com